ArticleCureus2026
Effectiveness and Safety of Rituximab in Filipino Patients With Relapsing-Remitting Multiple Sclerosis: A Real-World Retrospective Cohort Study in a Resource-Limited Setting.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis (MS) is a chronic autoimmune disorder requiring prompt initiation of disease-modifying therapies to mitigate long-term disability. In resource-limited settings like the Philippines, the high cost of approved therapies makes evaluating accessible, off-label high-efficacy treatments like rituximab a clinical priority.
objectiveTo evaluate the real-world efficacy and safety of off-label rituximab in patients with relapsing-remitting MS (RRMS) in a tertiary center in the Philippines.
methodsThis single-center retrospective cohort study involved 32 patients with RRMS treated with rituximab between 2017 and 2024. Primary outcomes included the proportion of patients free from clinical relapses, the annualized relapse rate (ARR), and disability progression (as measured by the Expanded Disability Status Scale (EDSS)). Achievement of No Evidence of Disease Activity (NEDA) was assessed, though limited by inconsistent MRI longitudinal data due to financial barriers. The study is further limited by its retrospective design, small sample size, and lack of a comparator arm.
resultsThe study included 32 patients (75% female) with a mean age of 25.7 + 8.5 years and a mean baseline EDSS of 1.5 +/- 1.3. Following rituximab initiation, the ARR was 0.55 +/- 0.75. At the two-year follow-up, 75% (n=24) of the cohort achieved NEDA; however, this assessment was based on available clinical and radiological data, as longitudinal MRI was incomplete for a subset of patients due to financial barriers. Disability levels remained stable, with no statistically significant change in mean EDSS from baseline. Rituximab was generally well-tolerated, with mild infusion-related reactions reported in 9.4% (n=3) of patients and no serious adverse events recorded.
conclusionIn this small observational cohort, rituximab showed potential effectiveness and favorable tolerability, suggesting it may be a viable therapeutic alternative for achieving NEDA in settings where socioeconomic barriers limit access to approved anti-CD20 agents. However, given the lack of a comparator arm and modest sample size, these findings should be interpreted with caution and do not imply therapeutic equivalence to standardized high-efficacy therapies. Larger, prospective comparative studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.